* Genocea Biosciences Inc GNCA.OQ GNCA.O is expected
to show a
rise in quarterly revenue when it reports results on April 27
(estimated).
* The Cambridge Massachusetts-based company is expected to
report
revenue of $566.67 thousand, according to the mean estimate from
3 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Genocea Biosciences
Inc
is for a loss of 18 cents per share. For the same quarter last
year, the company reported a loss of 17 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Genocea
Biosciences Inc is $6, above its last closing price of $0.42.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.20 -0.19 Beat 5
Sep. 30 2021 -0.20 -0.20 -0.05 Beat 74.7
Jun. 30 2021 -0.18 -0.18 -0.06 Beat 67
Mar. 31 2021 -0.20 -0.20 -0.17 Beat 14.1
Dec. -0.21 -0.21 -0.23 Missed -10.6
31 2020
Sep. 30 2020 -0.25 -0.24 -0.08 Beat 66.9
Jun. 30 2020 -0.41 -0.40 -0.39 Beat 3.7
Mar. 31 2020 -0.34 -0.35 -0.46 Missed -30.7
This summary was machine generated April 25 at 18:31 GMT. All
figures in US dollars unless otherwise stated